Towards a live oral vaccine against enterotoxigenic Escherichia coli of swine

Attridge, Stephen R.; Hackett, Jim; Morona, Renato; Whyte, P. B. D.

doi:10.1016/0264-410x(88)90134-x

Cited by 24 publications

(11 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Heterologous Ag delivery by Salmonella used to be largely dependent upon antibiotic selectable genes (37,38) or by alternative methods, including nonantibiotic-based vectors (39), balanced lethal stabilization systems (20,40), or by chromosomal insertions (41,42). Owing to the apparent drawbacks of stability and antibiotic gene leakage, the antibiotic-based vector delivery systems cannot be further developed for human use.…”

Section: Discussionmentioning

confidence: 99%

Oral Vaccination withSalmonellaSimultaneously ExpressingYersinia pestisF1 and V Antigens Protects against Bubonic and Pneumonic Plague

Yang

Hinnebusch

Trunkle

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

The gut provides a large area for immunization enabling the development of mucosal and systemic Ab responses. To test whether the protective Ags to Yersinia pestis can be orally delivered, the Y. pestis caf1 operon, encoding the F1-Ag and virulence Ag (V-Ag) were cloned into attenuated Salmonella vaccine vectors. F1-Ag expression was controlled under a promoter from the caf1 operon; two different promoters (P), PtetA in pV3, PphoP in pV4, as well as a chimera of the two in pV55 were tested. F1-Ag was amply expressed; the chimera in the pV55 showed the best V-Ag expression. Oral immunization with Salmonella-F1 elicited elevated secretory (S)-IgA and serum IgG titers, and Salmonella-V-Ag(pV55) elicited much greater S-IgA and serum IgG Ab titers than Salmonella-V-Ag(pV3) or Salmonella-V-Ag(pV4). Hence, a new Salmonella vaccine, Salmonella-(F1+V)Ags, made with a single plasmid containing the caf1 operon and the chimeric promoter for V-Ag allowed the simultaneous expression of F1 capsule and V-Ag. Salmonella-(F1+V)Ags elicited elevated Ab titers similar to their monotypic derivatives. For bubonic plague, mice dosed with Salmonella-(F1+V)Ags and Salmonella-F1-Ag showed similar efficacy (>83% survival) against ∼1000 LD50 Y. pestis. For pneumonic plague, immunized mice required immunity to both F1- and V-Ags because the mice vaccinated with Salmonella-(F1+V)Ags protected against 100 LD50 Y. pestis. These results show that a single Salmonella vaccine can deliver both F1- and V-Ags to effect both systemic and mucosal immune protection against Y. pestis.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral Vaccination withSalmonellaSimultaneously ExpressingYersinia pestisF1 and V Antigens Protects against Bubonic and Pneumonic Plague

Yang

Hinnebusch

Trunkle

et al. 2007

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…Since the initial proposal to use Salmonella organisms to deliver fimbrial antigens (3,31,42,50), construction of such recombinants that stably express high levels of CFA/I, K88, and K99 fimbriae has evolved from the utilization of antibioticbased vectors (3,50) and nonantibiotic-based vectors (for plasmid retention and antigen expression) (4,42) to the present well-established balanced lethal stabilization system in Salmonella (17,36,48). Here we report the construction of a bal- FIG.…”

Section: Discussionmentioning

confidence: 99%

“…ETEC virulence is also dependent on the expression of fimbrial colonization factor antigens, which mediate the colonization of the gastrointestinal tract (25,26,30). This heterogeneous group of fimbrial adhesins also dictates host specificity (1,3,25,26), and antibodies against these fimbriae have been implicated in protective immunity against ETEC infection in a number of animal and human systems (1,15,25,26,30,32).…”

mentioning

confidence: 99%

Oral Immunization with aSalmonella typhimuriumVaccine Vector Expressing Recombinant EnterotoxigenicEscherichia coliK99 Fimbriae Elicits Elevated Antibody Titers for Protective Immunity

et al. 1998

View full text Add to dashboard Cite

Bovine enterotoxigenic Escherichia coli (ETEC) continues to cause mortality in piglets and newborn calves. In an effort to develop a safe and effective vaccine for the prevention of F5+ ETEC infections, a balanced lethalasd + plasmid carrying the complete K99 operon was constructed and designated pMAK99-asd +. Introduction of this plasmid into an attenuated Salmonella typhimurium Δaro Δasd strain, H683, resulted in strain AP112, which stably expresses E. coli K99 fimbriae. A single oral immunization of BALB/c and CD-1 mice with strain AP112 elicited significant mucosal immunoglobulin A (IgA) titers that remained elevated for >11 weeks. IgA and IgG responses in serum specific for K99 fimbriae were also induced, with a prominent IgG1, as well as IgG2a and IgG2b, titer. To assess the derivation of these antibodies, a K99 isotype-specific B-cell ELISPOT analysis was conducted by using mononuclear cells from the lamina propria of the small intestines (LP), Peyer’s patches (PP), and spleens of vaccinated and control BALB/c mice. This analysis revealed elevated numbers of K99 fimbria-specific IgA-producing cells in the LP, PP, and spleen, whereas elevated K99 fimbria-specific IgG-producing cells were detected only in the PP and spleen. These antibodies were important for protective immunity. One-day-old neonates from dams orally immunized with AP112 were provided passive protection against oral challenge with wild-type ETEC, in contrast to challenged neonates from unvaccinated dams or from dams vaccinated with a control Salmonella vector. These results confirm that oral Salmonella vaccine vectors effectively deliver K99 fimbriae to mucosal inductive sites for sustained elevation of IgA and IgG antibodies and for eliciting protective immunity.

show abstract

“…Live oral vaccines still represent a more controlled and more effective way of specific immune prevention of neonatal diarrhoea as compared to the so-called "feed back" (feeding of diarrhoeal faecal material to pregnant sows, as practised on some farms). The use of recombinant Salmonella-vector vaccines expressing the necessary adhesive epitopes could also come into question (Attridge et al, 1988;Morona et al, 1994). Finally, it is hoped that more progress in the area of genetically engineered plants (containing the required antigens produced for feeding) will be made in the future.…”

Section: Prevention By Vaccination (Using Adhesins As Protective Antimentioning

confidence: 99%

Preface

Holzapfel¹,

Naughton²

2005

Microbial Ecology in Growing Animals

View full text Add to dashboard Cite

Enteric diseases of pigs and calves owing to Escherichia coli typically appear during the first few days (and weeks) of life. The so far recognized pathotypes of E. coli involved are the enterotoxic E. coli (ETEC), verotoxic E. coli (VTEC), enteropathogenic E. coli (EPEC), and necrotoxic E. coli (NTEC). The first step in the pathogenesis of all these types is to adhere to the intestinal microvilli with or without inducing morphological lesions and produce specific toxins acting locally on enterocytes and/or absorbed into the bloodstream. This action is assured by specific ligand (adhesins) and receptor interactions which are characteristic of the pathotypes involved and may vary according to the animal species. The host-adapted adhesin/receptor systems are targets of several preventive measures including vaccines, receptor blocking and breeding for genetic resistance. They also provide the basis for cross-species infections including zoonoses. Therefore they deserve the attention of epidemiologists, research scientists and technologists. Besides, they provide tools for increased understanding of molecular pathogenesis, and offer excellent models for comparative studies of different disease entities of enteric colibacillosis in humans.

show abstract

Towards a live oral vaccine against enterotoxigenic Escherichia coli of swine

Cited by 24 publications

References 8 publications

Oral Vaccination withSalmonellaSimultaneously ExpressingYersinia pestisF1 and V Antigens Protects against Bubonic and Pneumonic Plague

Oral Vaccination withSalmonellaSimultaneously ExpressingYersinia pestisF1 and V Antigens Protects against Bubonic and Pneumonic Plague

Oral Immunization with aSalmonella typhimuriumVaccine Vector Expressing Recombinant EnterotoxigenicEscherichia coliK99 Fimbriae Elicits Elevated Antibody Titers for Protective Immunity

Preface

Contact Info

Product

Resources

About